Literature DB >> 17615234

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.

Sjoerd H van der Burg1, Sytse J Piersma, Annemieke de Jong, Jeanette M van der Hulst, Kitty M C Kwappenberg, Muriel van den Hende, Marij J P Welters, Jon J Van Rood, Gert Jan Fleuren, Cornelis J M Melief, Gemma G Kenter, Rienk Offringa.   

Abstract

Because of their important role in the maintenance of self-tolerance, CD4(+) regulatory T cells prevent autoimmune diseases but also curtail the efficacy of T cell immune responses against cancers. We now show that this suppressive action of CD4(+) regulatory T cells is not limited to cancers displaying tumor-associated self antigens, such as melanomas, but also extends to human papillomavirus (HPV)-positive cervical cancers that express foreign tumor antigens. HPV-specific CD4(+) T cells isolated from lymph node biopsies of cervical cancer patients were found to suppress proliferation and cytokine (IFN-gamma, IL-2) production by responder T cells. The capacity of HPV-specific CD4(+) T cells to exert this suppressive effect depended on their activation by cognate HPV antigen and on close-range interactions with responder T cells. HPV-specific CD4(+) regulatory T cells were also retrieved from cervical cancer biopsies, suggesting that they interfere with the anti-tumor immune response at both the induction and effector levels. Our findings offer a plausible explanation for the observed failure of the tumor-specific immune response in patients with cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17615234      PMCID: PMC1924590          DOI: 10.1073/pnas.0704672104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  Antigen-induced regulatory T cells in autoimmunity.

Authors:  Matthias G von Herrath; Leonard C Harrison
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

2.  Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.

Authors:  Annemieke de Jong; Sjoerd H van der Burg; Kitty M C Kwappenberg; Jeanette M van der Hulst; Kees L M C Franken; Annemieke Geluk; Krista E van Meijgaarden; Jan Wouter Drijfhout; Gemma Kenter; Pieter Vermeij; Cornelis J M Melief; Rienk Offringa
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

3.  Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.

Authors:  Hiroshi Tanaka; Junta Tanaka; Jørgen Kjaergaard; Suyu Shu
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

4.  Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.

Authors:  M Evans; L K Borysiewicz; A S Evans; M Rowe; M Jones; U Gileadi; V Cerundolo; S Man
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

5.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

6.  Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy.

Authors:  Helen Y Wang; Dean A Lee; Guangyong Peng; Zhong Guo; Yanchun Li; Yukiko Kiniwa; Ethan M Shevach; Rong Fu Wang
Journal:  Immunity       Date:  2004-01       Impact factor: 31.745

7.  Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Gabriella Ferrandina; Alessia Buzzonetti; Francesco Legge; Vanda Salutari; Giovanni Scambia
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

Review 8.  Prevention of cervical cancer through papillomavirus vaccination.

Authors:  Ian H Frazer
Journal:  Nat Rev Immunol       Date:  2004-01       Impact factor: 53.106

9.  Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.

Authors:  Marij J P Welters; Annemieke de Jong; Susan J F van den Eeden; Jeanette M van der Hulst; Kitty M C Kwappenberg; Sabrin Hassane; Kees L M C Franken; Jan Wouter Drijfhout; Gert Jan Fleuren; Gemma Kenter; Cornelis J M Melief; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

10.  Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

Authors:  M K Levings; R Sangregorio; M G Roncarolo
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

View more
  75 in total

Review 1.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

2.  Regulatory and Exhausted T Cell Responses to AAV Capsid.

Authors:  Gwladys Gernoux; James M Wilson; Christian Mueller
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

3.  Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.

Authors:  Carlos A Ramos; Neeharika Narala; Gayatri M Vyas; Ann M Leen; Ulrike Gerdemann; Erich M Sturgis; Matthew L Anderson; Barbara Savoldo; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

Review 4.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 5.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

Review 6.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

7.  Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.

Authors:  S Daayana; E Elkord; U Winters; M Pawlita; R Roden; P L Stern; H C Kitchener
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

8.  Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice.

Authors:  Jinlin Liu; Ning Zhang; Qun Li; Weiwei Zhang; Fang Ke; Qibin Leng; Hong Wang; Jinfei Chen; Honglin Wang
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

9.  Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Authors:  Brian M Olson; Ewa Jankowska-Gan; Jordan T Becker; Dario A A Vignali; William J Burlingham; Douglas G McNeel
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

10.  Therapeutic vaccines against human papillomavirus and cervical cancer.

Authors:  Angel Cid-Arregui
Journal:  Open Virol J       Date:  2009-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.